Article info

Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial

Authors

  • Felix Eckstein Department of Imaging and Functional Musculoskeletal Research, Institute of Anatomy & Cell Biology, Paracelsus Medical University, Salzburg, Austria Chondrometrics GmbH, Ainring, Germany Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Paracelsus Medical University, Salzburg, Austria PubMed articlesGoogle scholar articles
  • Jeffrey L Kraines Global Clinical Development - Immunology, EMD Serono Research and Development Institute, Inc, Billerica, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Aida Aydemir Global Biostatistics and Epidemiology, EMD Serono Reserach and Development Institute, Inc, Billerica, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Wolfgang Wirth Department of Imaging and Functional Musculoskeletal Research, Institute of Anatomy & Cell Biology, Paracelsus Medical University, Salzburg, Austria Chondrometrics GmbH, Ainring, Germany Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Paracelsus Medical University, Salzburg, Austria PubMed articlesGoogle scholar articles
  • Susanne Maschek Department of Imaging and Functional Musculoskeletal Research, Institute of Anatomy & Cell Biology, Paracelsus Medical University, Salzburg, Austria Chondrometrics GmbH, Ainring, Germany PubMed articlesGoogle scholar articles
  • Marc C Hochberg University of Maryland School of Medicine, Baltimore, Maryland, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Felix Eckstein, Institute of Anatomy & Cell Biology, Paracelsus Medical University, Salzburg, Austria; felix.eckstein{at}pmu.ac.at
View Full Text

Citation

Eckstein F, Kraines JL, Aydemir A, et al
Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial

Publication history

  • Received October 9, 2019
  • Revised January 8, 2020
  • Accepted January 25, 2020
  • First published February 25, 2020.
Online issue publication 
March 19, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.